aPTT	Activated partial thromboplastin time
apoB	Apolipoprotein B
BCS	Biopharmaceutics Classification System
BDNF	Brain-derived neurotrophic factor
C10	Sodium caprate
CD	Circular dichroism
CHONAC	Choline salcaprozate (ionic liquid)
CI	Confidence interval
Cmax	Maximum plasma concentration
CMC	Critical micelle concentration
CRP	C-reactive protein
DMPC	Dimethylphosphatidylcholine
DVT	Deep vein thrombosis
EGF-A	Epidermal growth factor A (domain)
EMA	European Medicines Agency
ETD	Estimated treatment difference
FD4	FITC-dextran 4000
FDA	U.S. Food and Drug Administration
FaSSIF	Fasted State Simulated Intestinal Fluid
FeSSIF	Fed State Simulated Intestinal Fluid
FITC	Fluorescein isothiocyanate
GI	Gastrointestinal
GIP	Glucose-dependent insulinotropic polypeptide
GLP-1	Glucagon-like peptide-1
GLP-1RA(s)	GLP-1 receptor agonist(s)
GRAS	Generally recognized as safe
HbA1c	Glycated hemoglobin
HR	Hazard ratio
IU	International units
i.v.	Intravenous
Kd	Dissociation constant
LDL	Low-density lipoprotein
LDL-C	LDL cholesterol
LDLR	LDL receptor
LMWH	Low-molecular-weight heparin
Lp(a)	Lipoprotein(a)
MACE	Major adverse cardiovascular events
MCC	Microcrystalline cellulose
MPTP	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
NMR	Nuclear magnetic resonance
NOAEL	No observed adverse effect level
PCSK9	Proprotein convertase subtilisin/kexin type 9
PE(s)	Permeation enhancer(s)
Papp	Apparent permeability coefficient
PERMANOVA	Permutational multivariate analysis of variance
pKa	Acid dissociation constant
PVP	Polyvinylpyrrolidone (povidone)
RH	Relative humidity
s.c.	Subcutaneous
SEM	Semaglutide
ssNMR	Solid-state nuclear magnetic resonance
SNAC	Salcaprozate sodium (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate)
T2DM	Type 2 diabetes mellitus
TEER	Transepithelial electrical resistance
TFPI	Tissue factor pathway inhibitor
TNF-α	Tumor necrosis factor alpha
UFH	Unfractionated heparin
VTE	Venous thromboembolism